The bile acid membrane receptor TGR5: a novel pharmacological target in metabolic, inflammatory and neoplastic disorders

References

• Barrasa JI, Olmo N, Lizarbe MA, Turnay J. Bile acids in the colon, from healthy to cytotoxic molecules. Toxicol In Vitro 2013;27:964--77
   Google Scholar
• Russell DW. Fifty years of advances in bile acid synthesis and metabolism. J Lipid Res 2009;50:S120–5
   PubMedGoogle Scholar
• Mikov M, Fawcett JP, Kuhajda K, Kevresan S. Pharmacology of bile acids and their derivatives: absorption promoters and therapeutic agents. Eur J Drug Metab Pharmacokinet 2006;31:237–51
   PubMed Web of Science ®Google Scholar
• Stojancevic M, Stankov K, Mikov M. The impact of farnesoid X receptor activation on intestinal permeability in inflammatory bowel disease. Can J Gastroenterol 2012;6:631–7
   Google Scholar
• Kong B, Wang L, Chiang JY, et al. Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology 2012;56:1034–43
   PubMed Web of Science ®Google Scholar
• Keitel V, Kubitz R, Häussinger D. Endocrine and paracrine role of bile acids. World J Gastroenterol 2008;14:5620–9
   PubMed Web of Science ®Google Scholar
• Thomas C, Pellicciari R, Pruzanski M, et al. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 2008;7:678–93
   PubMed Web of Science ®Google Scholar
• Ranhotra HS. The mammalian orphan nuclear receptors: orphans as cellular guardians. J Recept Signal Transduct Res 2011;31:20–5
   PubMed Web of Science ®Google Scholar
• Moore DD, Kato S, Xie W, et al. International Union of Pharmacology. LXII. The NR1H and NR1I receptors: constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, farnesoid X receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor. Pharmacol Rev 2006;58:742–59
   PubMed Web of Science ®Google Scholar
• Kawamata Y, Fujii R, Hosoya M, et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem 2003;278:9435–40
   PubMed Web of Science ®Google Scholar
• Raufman JP, Cheng K, Zimniak P. Activation of muscarinic receptor signaling by bile acids: physiological and medical implications. Dig Dis Sci 2003;48:1431–44
   Google Scholar
• Ferrari C, Macchiarulo A, Costantino G, Pellicciari R. Pharmacophore model for bile acids recognition by the FPR receptor. J Comput Aided Mol Des 2006;20:295–303
   PubMed Web of Science ®Google Scholar
• Pols TW, Noriega LG, Nomura M, et al. The bile acid membrane receptor TGR5: a valuable metabolic target. Dig Dis 2011;29:37–44
   PubMed Web of Science ®Google Scholar
• Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009;89:147–91
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Mencarelli A, Palladino G, Cipriani S. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol Sci 2009;30:570–80
   PubMed Web of Science ®Google Scholar
• Maruyama T, Miyamoto Y, Nakamura T, et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun 2002;298:714–9
   PubMed Web of Science ®Google Scholar
• Keitel V, Häussinger D. Perspective: TGR5 (Gpbar-1) in liver physiology and disease. Clin Res Hepatol Gastroenterol 2012;36:412–9
   PubMed Web of Science ®Google Scholar
• Keitel V, Görg B, Bidmon HJ, et al. The bile acid receptor TGR5 (Gpbar-1) acts as a neurosteroid receptor in brain. Glia 2010;58:1794–805
   PubMed Web of Science ®Google Scholar
• Sharma R, Long A, Gilmer JF. Advances in bile acid medicinal chemistry. Curr Med Chem 2011;18:4029–52
   PubMed Web of Science ®Google Scholar
• Halpin HA, Morales-Suárez-Varela MM, Martin-Moreno JM. Chronic disease prevention and the new public health. Public Health Reviews 2010;32:120–154
   Google Scholar
• Zarrinpar A, Loomba R. Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012;36:909–21
   PubMed Web of Science ®Google Scholar
• Shantikumar S, Caporali A, Emanueli C. Role of microRNAs in diabetes and its cardiovascular complications. Cardiovasc Res 2012;93:583–93
   Google Scholar
• Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131–57
   PubMed Web of Science ®Google Scholar
• Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009;5:262–9
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Radermecker RP. Addition of incretin therapy to metformin in type 2 diabetes. The Lancet 2010;375:1410–12
   PubMed Web of Science ®Google Scholar
• Drucker DJ. The biology of incretin hormones. Cell Metab 2006;3:153–65
   PubMed Web of Science ®Google Scholar
• Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun 2005;329:386–90
   PubMed Web of Science ®Google Scholar
• Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009;10:167–77
   PubMed Web of Science ®Google Scholar
• Thomas C, Auwerx J, Schoonjans K. Bile acids and the membrane bile acid receptor TGR5–connecting nutrition and metabolism. Thyroid 2008;18:167–74
   PubMed Web of Science ®Google Scholar
• Harach T, Pols TW, Nomura M, et al. TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Sci Rep 2012;2:430
   PubMed Web of Science ®Google Scholar
• De Marinis YZ, Salehi A, Ward CE, et al. GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2 + channel-dependent exocytosis. Cell Metab 2010;11:543–53
   PubMed Web of Science ®Google Scholar
• Knop FK. Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes? Am J Physiol Endocrinol Metab 2010;299:E10–13
   Google Scholar
• Witkamp RF. Current and Future Drug Targets in Weight Management. Pharm Res 2011;28:1792–818
   PubMed Web of Science ®Google Scholar
• Brubaker PL. Incretin-based therapies: mimetics versus protease inhibitors. Trends Endocrinol Metab 2007;18:240–5
   Google Scholar
• Pols TW, Auwerx J, Schoonjans K. Targeting the TGR5-GLP-1 pathway to combat type 2 diabetes and non-alcoholic fatty liver disease. Gastroenterol Clin Biol 2010;34:270–3
   PubMedGoogle Scholar
• Pols TW, Noriega LG, Nomura M, et al. The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. J Hepatol 2011;54:1263–72
   PubMed Web of Science ®Google Scholar
• Watanabe M, Houten SM, Mataki C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006;439:484–9
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Cipriani S, Baldelli F, Mencarelli A. Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. Prog Lipid Res 2010;49:171–85
   PubMed Web of Science ®Google Scholar
• Maruyama T, Tanaka K, Suzuki J, et al. Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-Bar) in mice. J Endocrinol 2006;191:197–205
   PubMed Web of Science ®Google Scholar
• Vassileva G, Hu W, Hoos L, et al. Gender-dependent effect of Gpbar1 genetic deletion on the metabolic profiles of diet-induced obese mice. J Endocrinol 2010;205:225–32
   PubMed Web of Science ®Google Scholar
• Brufau G, Bahr MJ, Staels B, et al. Plasma bile acids are not associated with energy metabolism in humans. Nutr Metab (Lond) 2010;7:73
   Google Scholar
• Tornatore L, Thotakura AK, Bennett J, et al. The nuclear factor kappa B signaling pathway: integrating metabolism with inflammation. Trends Cell Biol 2012;22:557–66
   PubMed Web of Science ®Google Scholar
• Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010;72:219–46
   PubMed Web of Science ®Google Scholar
• Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004;431:461–6
   PubMed Web of Science ®Google Scholar
• Yoshizaki T, Schenk S, Imamura T, et al. SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity. Am J Physiol Endocrinol Metab 2010;298:E419–28
   PubMed Web of Science ®Google Scholar
• Calmus Y, Guechot J, Podevin P, et al. Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor-alpha production by monocytes. Hepatology 1992;16:719–23
   PubMed Web of Science ®Google Scholar
• Keitel V, Donner M, Winandy S, et al. Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem Biophys Res Commun 2008;372:78–84
   PubMed Web of Science ®Google Scholar
• Porez G, Prawitt J, Gross B, Staels B. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J Lipid Res 2012;53:1723–37
   PubMed Web of Science ®Google Scholar
• Businaro R, Tagliani A, Buttari B, et al. Cellular and molecular players in the atherosclerotic plaque progression. Ann N Y Acad Sci 2012;1262:134–41
   Google Scholar
• Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circ J 2010;74:213–20
   PubMed Web of Science ®Google Scholar
• Andrés V, Pello OM, Silvestre-Roig C. Macrophage proliferation and apoptosis in atherosclerosis. Curr Opin Lipidol 2012;23:429–38
   PubMed Web of Science ®Google Scholar
• Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol 2009;6:399–409
   PubMed Web of Science ®Google Scholar
• Pols TWH, Nomura M, Harach T, et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab 2011;14:747–57
   PubMed Web of Science ®Google Scholar
• Yoshimura T, Kurita C, Nagao T, et al. Inhibition of tumor necrosis factor-alpha and interleukin-1-beta production by beta-adrenoreceptor agonists from lipopolysaccharide-stimulated human peripheral blood mononuclear cells. Pharmacology 1997;54:144–52
   PubMed Web of Science ®Google Scholar
• Baker RG, Hayden MS, Ghosh S. NF-κB, inflammation, and metabolic disease. Cell Metab 2011;13:11–22
   PubMed Web of Science ®Google Scholar
• Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004;6:203–8
   PubMed Web of Science ®Google Scholar
• Wang YD, Chen WD, Yu D, et al. The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor κ light-chain enhancer of activated B cells (NF-κB) in mice. Hepatology 2011;54:1421–32
   PubMed Web of Science ®Google Scholar
• Ferreira V, van Dijk KW, Groen AK, et al. Macrophage-specific inhibition of NF-kappaB activation reduces foam cell formation. Atherosclerosis 2007;192:283–90
   Google Scholar
• Cipriani S, Mencarelli A, Chini MG, et al. The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS One 2011;6:e25637
   PubMed Web of Science ®Google Scholar
• Clements WD, McCaigue M, Erwin P, et al. Biliary decompression promotes Kupffer cell recovery in obstructive jaundice. Gut 1996;38:925–31
   Google Scholar
• Baffy G. Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J Hepatol 2009;51:212–23
   PubMed Web of Science ®Google Scholar
• Sung JJ, Go MY. Reversible Kupffer cell suppression in biliary obstruction is caused by hydrophobic bile acids. J Hepatol 1999;30:413–8
   Google Scholar
• Van Bossuyt H, Desmaretz C, Gaeta GB, Wisse E. The role of bile acids in the development of endotoxemia during obstructive jaundice in the rat. J Hepatol 1990;10:274–9
   PubMed Web of Science ®Google Scholar
• Scott-Conner CE, Grogan JB, Scher KS, et al. Impaired bacterial killing in early obstructive jaundice. Am J Surg 1993;166:308–10
   PubMed Web of Science ®Google Scholar
• Deitch EA, Sittig K, Li M, et al. Obstructive jaundice promotes bacterial translocation from the gut. Am J Surg 1990;159:79–84
   PubMed Web of Science ®Google Scholar
• Karin M, Greten FR. NF-kappa B; linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005;5:749–59
   PubMed Web of Science ®Google Scholar
• Keitel V, Reinehr R, Gatsios P, et al. The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology 2007;45:695–704
   PubMed Web of Science ®Google Scholar
• Cheluvappa R, Denning GM, Lau GW, et al. Pathogenesis of the hyperlipidemia of Gram-negative bacterial sepsis may involve pathomorphological changes in liver sinusoidal endothelial cells. Int J Infect Dis 2010;14:e857–67
   Google Scholar
• Duryee MJ, Freeman TL, Willis MS, et al. Scavenger receptors on sinusoidal liver endothelial cells are involved in the uptake of aldehyde-modified proteins. Mol Pharmacol 2005;68:1423–30
   Google Scholar
• Knolle PA, Limmer A. Control of immune responses by scavenger liver endothelial cells. Swiss Med Wkly 2003;133:501–6
   Google Scholar
• Keitel V, Burdelski M, Warskulat U, et al. Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. Hepatology 2005;41:1160–72
   PubMed Web of Science ®Google Scholar
• Reinehr R, Häussinger D. Inhibition of bile salt-induced apoptosis by cyclic AMP involves serine/threonine phosphorylation of CD95. Gastroenterology 2004;126:249–62
   PubMedGoogle Scholar
• Reinehr R, Häussinger D. CD95 death receptor and epidermal growth factor receptor (EGFR) in liver cell apoptosis and regeneration. Arch Biochem Biophys 2012;518:2–7
   PubMed Web of Science ®Google Scholar
• Theodorakis NG, Wang YN, Skill NJ, et al. The role of nitric oxide synthase isoforms in extrahepatic portal hypertension: studies in gene-knockout mice. Gastroenterology 2003;124:1500–8
   Google Scholar
• Iwakiri Y. The molecules: mechanisms of arterial vasodilatation observed in the splanchnic and systemic circulation in portal hypertension. J Clin Gastroenterol 2007;41:S288–94
   PubMedGoogle Scholar
• Theodorakis NG, Wang YN, Wu JM, et al. Role of endothelial nitric oxide synthase in the development of portal hypertension in the carbon tetrachloride-induced liver fibrosis model. Am J Physiol Gastrointest Liver Physiol 2009;297:G792–9
   Google Scholar
• Li N, Wang X, Li T, et al. Identification of circulatory and excretory metabolites of a novel nitric oxide donor ZJM-289 in rat plasma, bile, urine and faeces by liquid chromatography-tandem mass spectrometry. Xenobiotica 2011;41:805–17
   PubMed Web of Science ®Google Scholar
• Keitel V, Cupisti K, Ullmer C, et al. The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology 2009;50:861–70
   PubMed Web of Science ®Google Scholar
• Keitel V, Ullmer C, Häussinger D. The membrane-bound bile acid receptor TGR5 (Gpbar-1) is localized in the primary cilium of cholangiocytes. Biol Chem 2010;391:785–9
   PubMed Web of Science ®Google Scholar
• Keitel V, Häussinger D. TGR5 in the biliary tree. Dig Dis 2011;29:45–7
   Google Scholar
• Li T, Holmstrom SR, Kir S, et al. The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling. Mol Endocrinol 2011;25:1066–71
   PubMed Web of Science ®Google Scholar
• Lavoie B, Balemba OB, Godfrey C, et al. Hydrophobic bile salts inhibit gallbladder smooth muscle function via stimulation of GPBAR1 receptors and activation of KATP channels. J Physiol 2010;588:3295–305
   PubMed Web of Science ®Google Scholar
• Marucci L, Alpini G, Glaser SS, et al. Taurocholate feeding prevents CCl4-induced damage of large cholangiocytes through PI3-kinase-dependent mechanism. Am J Physiol Gastrointest Liver Physiol 2003;284:G290–301
   Google Scholar
• Ueno Y, Francis H, Glaser S, et al. Taurocholic acid feeding prevents tumor necrosis factor-alpha-induced damage of cholangiocytes by a PI3K-mediated pathway. Exp Biol Med (Maywood) 2007;232:942–9
   Google Scholar
• Esposito K, Chiodini P, Colao A, et al. Metabolic Syndrome and Risk of Cancer: A systematic review and meta-analysis. Diabetes Care 2012;35:2402–11
   PubMed Web of Science ®Google Scholar
• Siddiqui AA. Metabolic syndrome and its association with colorectal cancer: a review. Am J Med Sci 2011;341:227–31
   PubMed Web of Science ®Google Scholar
• Hursting SD, Hursting MJ. Growth signals, inflammation, and vascular perturbations: mechanistic links between obesity, metabolic syndrome, and cancer. Arterioscler Thromb Vasc Biol 2012;32:1766–70
   PubMed Web of Science ®Google Scholar
• Siegel AB, Lim EA, Wang S, et al. Diabetes, body mass index, and outcomes in hepatocellular carcinoma patients undergoing liver transplantation. Transplantation 2012;94:539–43
   PubMed Web of Science ®Google Scholar
• Yang JI, Yoon JH, Myung SJ, et al. Bile acid-induced TGR5-dependent c-Jun-N terminal kinase activation leads to enhanced caspase 8 activation in hepatocytes. Biochem Biophys Res Commun 2007;361:156–61
   PubMed Web of Science ®Google Scholar
• Chen WD, Yu D, Forman BM, et al. The deficiency of G-protein-coupled bile acid receptor gpbar1 (TGR5) enhances chemically-induced liver carcinogenesis. Hepatology 2013;57:656–66
   Google Scholar
• Kortylewski M, Xin H, Kujawski M, et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 2009;15:114–23
   PubMed Web of Science ®Google Scholar
• Huang C, Xie K. Crosstalk of Sp1 and Stat3 signaling in pancreatic cancer pathogenesis. Cytokine Growth Factor Rev 2012;23:25–35
   PubMed Web of Science ®Google Scholar
• Yoon JH, Higuchi H, Werneburg NW, et al. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology 2002;122:985–93
   PubMed Web of Science ®Google Scholar
• Yasuda H, Hirata S, Inoue K, et al. Involvement of membrane-type bile acid receptor M-BAR/TGR5 in bile acid-induced activation of epidermal growth factor receptor and mitogen-activated protein kinases in gastric carcinoma cells. Biochem Biophys Res Commun 2007;354:154–9
   PubMed Web of Science ®Google Scholar
• Jürgens S, Meyer F, Spechler SJ, Souza R. The role of bile acids in the neoplastic progression of Barrett′s esophagus-a short representative overview. Z Gastroenterol 2012;50:1028–34
   PubMed Web of Science ®Google Scholar
• Hong J, Behar J, Wands J, et al. Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma. Gut 2010;59:170–80
   Web of Science ®Google Scholar
• Casaburi I, Avena P, Lanzino M, et al. Chenodeoxycholic acid through a TGR5-dependent CREB signaling activation enhances cyclin D1 expression and promotes human endometrial cancer cell proliferation. Cell Cycle 2012;11:2699–710
   PubMed Web of Science ®Google Scholar
• Sato H, Genet C, Strehle A, et al. Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europaea. Biochem Biophys Res Commun 2007;362:793–8
   PubMed Web of Science ®Google Scholar
• Genet C, Strehle A, Schmidt C, et al. Structure-activity relationship study of betulinic acid, a novel and selective TGR5 agonist, and its synthetic derivatives: potential impact in diabetes. J Med Chem 2010;53:178–90
   PubMed Web of Science ®Google Scholar
• Pellicciari R, Gioiello A, Macchiarulo A, et al. Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity. J Med Chem 2009;52:7958–61
   PubMed Web of Science ®Google Scholar
• Evans KA, Budzik BW, Ross SA, et al. Discovery of 3-aryl-4-isoxazolecarboxamides as TGR5 receptor agonists. J Med Chem 2009;52:7962–5
   PubMed Web of Science ®Google Scholar
• Perides G, Laukkarinen JM, Vassileva G, Steer ML. Biliary acute pancreatitis in mice is mediated by the G-protein-coupled cell surface bile acid receptor Gpbar1. Gastroenterology 2010;138:715–25
   PubMed Web of Science ®Google Scholar
• Stanimirov B, Stankov K, Mikov M. Pleiotropic functions of bile acids mediated by the farnesoid X receptor. Acta Gastroenterol Belg 2012;75:389–98
   PubMed Web of Science ®Google Scholar
• Charmot D. Non-systemic drugs: a critical review. Curr Pharm Des 2012;18:1434–45
   PubMed Web of Science ®Google Scholar
• Meissner M, Wolters H, de Boer RA, et al. Bile acid sequestration normalizes plasma cholesterol and reduces atherosclerosis in hypercholesterolemic mice. No additional effect of physical activity. Atherosclerosis 2013;27:964--77
   Google Scholar
• Handelsman Y. Role of bile acid sequestrants in the treatment of type 2 diabetes. Diabetes Care 2011;34:S244–50
   PubMedGoogle Scholar
• Stein SA, Lamos EM, Davis SN. A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf 2013;12:153–75
   PubMed Web of Science ®Google Scholar
• Holst JJ, McGill MA. Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants. Clin Drug Investig 2012;32:1–14
   Google Scholar
• Zarrinpar A, Loomba R. Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012;36:909–21
   PubMed Web of Science ®Google Scholar
• Potthoff MJ, Potts A, He T, et al. Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. Am J Physiol Gastrointest Liver Physiol. 2013;304:G371–80
   PubMed Web of Science ®Google Scholar